Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | EED | O75530 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793134 | 0.79 | MTNR1A (0.49) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL347860 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL3794946 | 0.75 | MTNR1A (0.51) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL7278098 | 0.74 | TDP1 (0.47) | MTNR1A | |
| SCHEMBL9911545 | 0.72 | MTNR1A (0.47) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL2094789 | 0.72 | EED (0.44) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL9911358 | 0.72 | GABRA1 (0.48) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL5986566 | 0.71 | MTNR1A (0.49) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL27921496 | 0.71 | EED (0.46) | MTNR1AMTNR1BEEDOPRM1OPRK1 | |
| SCHEMBL5357479 | 0.71 | MAOB (0.47) | MTNR1AMTNR1BEEDOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | MTNR1A 32/4885MTNR1B 39/4885EED 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.